Clinical Trial Update: A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3, multi-center trial evaluating gemcitabine/carboplatin with or without iniparib (BSI-201) in ER-, PR-, Her2-negative metastatic breast cancer; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Gemcitabine (Gemcitabine)
• Iniparib (BSI-201) (iniparib)

Snippet

Sponsor: Sanofi | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED